BMS Starts Nivolumab China Study Amid Rising Local Competition
This article was originally published in PharmAsia News
Major US immuno-oncology player Bristol-Myers Squibb is racing to gain a nod for Opdivo in China, where a dozen or so companies are already developing PD-1 and PD-1 inhibitors, one of which has been out-licensed to Merck & Co.
You may also be interested in...
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.
One year after the first cases of a novel coronavirus emerged in Wuhan, a team from the World Health Organization has arrived in the city to investigate its origin. Meanwhile, mixed results are reported for some of the leading Chinese vaccines being developed to fight the pandemic still wreaking global havoc.
China's innovative drug makers step into the spotlight by grabbing green lights for cancer drugs in the country's latest batch of product approvals.